Related Experiment Video
Updated: May 2, 2026

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
Anticancer activity of new coumarin substituted hydrazide-hydrazone derivatives
Tamer Nasr1, Samir Bondock2, Mahmoud Youns3
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Helwan, Egypt.
Abstract:
Drug resistance is a major impediment for cancer treatment, to overcome it we designed and synthesized sixteen coumarins bearing hydrazide-hydrazone moiety and evaluated them against human drug-resistant pancreatic carcinoma (Panc-1) cells and drug-sensitive (hepatic carcinoma; Hep-G2 and leukemia; CCRF) cell lines in vitro. The 6-brominated coumarin hydrazide-hydrazone derivatives (BCHHD) 7c, 8c and 10c were more potent than doxorubicin (DOX) against resistant Panc-1 cells. BCHHD 7c showed significant cytotoxicity against all tested cells (IC50: 3.60-6.50 μM) on comparison with all other coumarin hydrazide-hydrazone derivatives (CHHD), whereas BCHHD's 8c and 10c showed significant antiproliferative activity only against resistant Panc-1 cells with IC50 of 2.02 μM and 2.15 μM, respectively. All the investigated BCHHD's were able to activate caspases 3/7 and they could induce apoptosis in resistant Panc-1 cells. Microarray analysis showed that BCHHD 7c induced the expression of apoptotic- and cell cycle arrest (G2/M)- genes in resistant Panc-1 cells. Moreover, BCHHD 7c induced the up-regulation of CDKN1A, DDIT4, GDF-15 and down-regulation of CDC2, CDC20, CDK2 genes. Based on our results, we conclude that 7c could be a potent anticancer drug to overcome drug resistance in cancer and it could be highly beneficial for patients in the clinic.
Insights
Novel coumarin derivatives combat drug-resistant cancer. Compound 7c shows potent anticancer activity by inducing apoptosis and cell cycle arrest in resistant pancreatic cancer cells, offering hope for improved patient outcomes.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Pharmacology
Background:
- Drug resistance is a significant challenge in cancer therapy.
- Developing novel agents to overcome resistance is crucial.
Purpose of the Study:
- To design and synthesize novel coumarin hydrazide-hydrazone derivatives.
- To evaluate their efficacy against drug-resistant and drug-sensitive cancer cell lines.
- To investigate their mechanism of action.
Main Methods:
- Synthesis of sixteen coumarin hydrazide-hydrazone derivatives.
- In vitro evaluation against human pancreatic (Panc-1), hepatic (Hep-G2), and leukemia (CCRF) cell lines.
- Assays for cytotoxicity, caspase-3/7 activation, apoptosis induction, and gene expression (microarray).
Main Results:
- 6-Brominated coumarin hydrazide-hydrazone derivatives (BCHHDs) 7c, 8c, and 10c demonstrated superior potency against resistant Panc-1 cells compared to doxorubicin.
- BCHHD 7c exhibited significant cytotoxicity across all tested cell lines (IC50: 3.60–6.50 μM).
- BCHHDs activated caspases 3/7, induced apoptosis in Panc-1 cells, and modulated key genes involved in apoptosis and cell cycle arrest (G2/M).
Conclusions:
- BCHHD 7c is a potent anticancer agent effective against drug-resistant cancer.
- The compound induces apoptosis and cell cycle arrest, highlighting its therapeutic potential.
- 7c may offer a promising strategy to overcome drug resistance in clinical cancer treatment.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
06:34Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides CHIPS
Published on: June 20, 2014
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Inhibition of Cdk Activity